Evaluation of Security and Efficacy of Medtrum Hybrid Closed Loop System in Children, Adolescents and Adults With Type 1 Diabetes

Status: Recruiting
Location: See all (17) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

The purpose of this study is to evaluate the safety and effectiveness of the MEDTRUM Hybrid Closed Loop (HCL) System in children, adolescents, and adults with type 1 diabetes (7-75 years old) in a home setting and to test the function of meal announcement in an extend study. The main question it aims to answer is : • Is the Hybrid Closed Loop system superior at increasing the time spent in the target glucose range of 70-180 mg/dL when compared to the Open (manual) Loop system ? Participants will be : * Trained into the use of the Insulin pump MEDTRUM A8 TouchCare® Insulin Management system * Randomized to the Open Loop or Closed Loop group * Respond to self administered questionnaires : the Hypoglycaemia Fear Survey, the Diabetes Quality of Life Questionnaire, and the Diabetes treatment Satisfaction Questionnaire status Researchers will compare the time spent in the target glucose range of 70-180 mg/mL during the last 12 weeks of the study between the patients randomised to the Open Loop group and those randomised to the Closed Loop group.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 7
Maximum Age: 75
Healthy Volunteers: f
View:

• Patients living with Type 1 diabetes:

‣ adults aged 18 to 75 years old (included)

⁃ children/adolescents aged 7 or older

• Total daily dose of insulin ≥ 10 units per day \& weighing \>22 Kg

• Patient and their parent(s)/guardian(s) trained and able to count carb

• Current or previous insulin pump user or patient treated with multiple insulin injections

• Patient glycaemic target is not achieved or suboptimal according to international consensus: HbA1c level equal and greater than 7% and less than 12% at the time of enrolment, or TIR \< 70%, or TBR \>4%

• Any type of rapid insulin with a total daily insulin in the range of 10-60 IU (unauthorized use of insulin supplements by pen injector): Humalog™, Lyumjev (insulin lispro injection), Novorapid (insulin aspart) or FIASP® ( faster insulin aspart )

• Subject and their parent(s)/guardian(s) able to receive and understand study information, give written informed consent, and easily participate to the trial

• Subject and their parent(s)/guardian(s) affiliated to the French social security system

• Subject and their parent(s)/guardian(s) have the cognitive ability and can successfully operate all study devices and can adhere to the protocol

Locations
Other Locations
France
CHU Angers
NOT_YET_RECRUITING
Angers
CHU Besançon
NOT_YET_RECRUITING
Besançon
CHU Bordeaux
NOT_YET_RECRUITING
Bordeaux
CHU Caen
NOT_YET_RECRUITING
Caen
Centre Hospitalier Sud-Francilien
RECRUITING
Corbeil-essonnes
Centre Hospitalier de Gonesse
RECRUITING
Gonesse
Centre Hospitalier Saint-Louis
NOT_YET_RECRUITING
La Rochelle
Hôpital Hôtel-Dieu
RECRUITING
Le Creusot
Hospices Civils de Lyon
NOT_YET_RECRUITING
Lyon
Hôpital Européen
NOT_YET_RECRUITING
Marseille
Hôpital La Timone
NOT_YET_RECRUITING
Marseille
CHU Montpellier
NOT_YET_RECRUITING
Montpellier
CHU Nantes
NOT_YET_RECRUITING
Nantes
Hôpital Lariboisière
NOT_YET_RECRUITING
Paris
Hôpital Necker
NOT_YET_RECRUITING
Paris
Hôpital Robert Debré
NOT_YET_RECRUITING
Paris
Hôpital Rangueil
NOT_YET_RECRUITING
Toulouse
Contact Information
Primary
Mélanie MARMOUNIER
melanie.marmounier@medtrum.fr
0620591224
Backup
Doris BARNIER-RIPET
seecloop@axonal.com
0776151479
Time Frame
Start Date: 2024-04-15
Estimated Completion Date: 2025-12
Participants
Target number of participants: 160
Treatments
Open Loop
Patients using the Insulin Management System device in a manual mode of operation. Patient must use the interface directly to deliver insulin. The algorithm will not be activated.
Closed Loop
Patients using the Insulin Management System device in the Closed Loop mode of operation. The algorithm will be activated. The algorithm is capable of delivery of insulin based on sensor derived glucose levels, glucose level trends and insulin pump delivery history.~Patients in this group can continue to an exploratory phase for the Automatic Meal Management function.
Related Therapeutic Areas
Sponsors
Collaborators: Axonal-Biostatem
Leads: Medtrum France

This content was sourced from clinicaltrials.gov

Similar Clinical Trials